BMY Stock Analysis: Buy, Sell, or Hold?
BMY - Bristol-Myers Squibb Co.
$55.05
0.77 (1.42%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 05, 2026
4d
Get Alerted When BMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called BMY this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMY shows positive signals but monitor for confirmation. Market pricing in 0.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BMY shows positive signals but monitor for confirmation. Market pricing in 0.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$55.74
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$34.61
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMY is currently trading at $55.05, which is considered fair relative to its 30-day fair value range of $53.97 to $55.88. The stock's valuation (Forward PE: 9.0) is in line with its historical norms (8.9). At these levels, the market is pricing in 0.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BMY is in a strong uptrend. The price is currently testing key support at $53.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMY is in a strong uptrend. The price is currently testing key support at $53.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$53.97 -
$55.88
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($58.04)
- NEUTRAL: Market pricing in 0.6% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$53.97 -
$55.88
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$53.55
Resistance Level
$56.56
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
9.03
Wall Street Target
$58.04
(+6.9%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
80.9%
Profit Margin
12.6%
Valuation Premium vs History
+0.6% premium
PE vs Historical
9.0 vs 8.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.6%
(market-implied from PE analysis)
1-Year Target
$54.61
(+1%)
2-Year Target
$54.93
(+1%)
3-Year Target
$55.26
(+2%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
PE COMPRESSION
$54.46
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -2.3%)
$124.85
(+130%)
Base:
(SPY PE: 9.0, Growth: -2.3%)
$50.56
(-7%)
Bear:
(PE: 7.7, Growth: -2.3%)
$42.97
(-21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 18.39 | Current EPS (TTM): $2.97
Bull Case
$120.16
(+118%)
Analyst growth 100.0%, PE expands to 20.2
Base Case
$109.24
(+98%)
Market implied 100.0%, PE stable at 18.4
Bear Case
$37.14
(-33%)
Severe decline -20.0%, PE contracts to 15.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 7:49 PM ET
Data refreshes hourly during market hours. Next update: 8:49 PM
Data refreshes hourly during market hours. Next update: 8:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMY showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2025-09-29
Ro Khanna
BUY
2025-09-05
David V Elkins
SELL
56000 shares
2025-09-02
Featured in Portfolios
BMY is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced BMY Option Strategies
Professional options setups generated by AI based on today's BMY price and gamma walls.
